On May 28, 2025, Immunic, Inc. announced the commencement of a public offering of pre-funded warrants and series A and B warrants for its common stock. They also presented new data from their phase 2 CALLIPER trial for vidofludimus calcium, targeting progressive multiple sclerosis.